GUMDROP : JHMI J1156 Randomized, Open Label Phase 3 Study Comparing Cabazitaxel at 20 mg per m2 and at 25 mg per m2 Every 3 Weeks in Combination with Prednisone for mCRPC Previously Treated with a Docetaxel Containing Regimen

Created by Channing Paller, last modified on Apr 14, 2012

Description:

CRPC progressed = 6 months after prior HT during or after docetaxel-containing therapy; NO prior mitoxantrone or cabazitaxel

Link:

http://clinicaltrials.gov/ct2/show/NCT01308580

Site:

Johns Hopkins Hospital

Principal Investigator:

Mario Eisenberger, M.D.